ASGN Stock Study (2-16-23)

I recently did a stock study on ASGN Inc. (ASGN) with a closing price of $92.72.

M* writes:

     > ASGN Inc is a provider of information technology (IT) services
     > and professional solutions, including technology, creative,
     > and digital, across the commercial and government sectors.

This medium-sized company has grown sales and earnings at annualized rates of 12.6% and 19.5% over the last 10 years. Lines are mostly up, straight, and parallel except for dips in EPS (’15) and sales (’20). PTPM has increased from 5.7% (’13) to 7.9% (’22) with a last-5-year average of 6.9%. This is slightly higher than peer averages while trailing the industry.

ROE has increased from 8.9% (’13) to 13.8% (’22) with a last-5-year average of 13.2%. Again, this is slightly better than peer averages while trailing the industry. Debt-to-Capital has averaged 43% over the last five years, which is slightly higher than peer averages and much lower than the industry. Interest Coverage is 10 and Quick Ratio is 2.21. Value Line gives APD a B+ for financial strength.

I assume long-term annualized sales growth of 6% based on the following:

• CNN Business projects 2.2% YOY and 4.3% per year for ’23 and ’22-’24, respectively (based on 6 analysts).
• YF projects YOY growth of 3.4% and 5.4% for ’23 and ’24, respectively (7 analysts).
• Zacks projects YOY 2.4% and 5.9% for ’23 and ’24, respectively (3).
• Value Line projects 8.4% annualized from ’21-’26.
• CFRA projects 3.2% YOY and 4.2% per year for ’23 and ’22-’24 (6).
• M* gives a 2-year annualized estimate of 3.4%.

This is admittedly not a conservative forecast. I am projecting sales to pick up after the next couple years.

I assume long-term annualized EPS growth of 8% based on the following:

• CNN Business projects a 3.5% YOY contraction and 5.1% growth per year for ’23 and ’22-’24, respectively (based on 6 analysts), along with 5-year annualized growth of 10.9%.
• Nasdaq.com projects 13.4% YOY growth for ’24 (3 analysts).
• Seeking Alpha projects 5-year annualized growth of 10.3%.
• YF projects YOY 3.7% contraction and 14.4% growth for ’23 and ’24, respectively (7), along with 5-year annualized growth of 10.9%.
• Zacks projects YOY 3.7% contraction and 13.5% growth for ’23 and ’24, respectively (3), along with 5-year annualized growth of 10.9%.
• Value Line projects annualized growth of 10.9% from ’21-’26.
• CFRA projects growth of 23.4% YOY and 17.9% per year for ’23 and ’22-’24, respectively (7).

I am projecting below the entire range of five long-term estimates (mean 10.8%).

My Forecast High P/E is 22. High P/E has ranged from 22.1 (’17) to 37.8 (’15) with a last-5-year average of 26.5. It seems to be trending lower. I am projecting just below the range.

My Forecast Low P/E is 14. Low P/E has ranged from 7.7 (downside outlier in ’20) to 22.7 (’15) with a last-5-year average (excluding ’20) of 16.5. It also seems to be trending lower. Only the outlier is less than my projection.

My Low Stock Price Forecast is the default $72.80. This is 21.5% below the previous closing price and below ’21 and ’22 lows.

These inputs land ASGN in the BUY zone with an U/D ratio of 3.8. The Total Annualized Return is 12.7%.

PAR (using forecast average, not high, P/E) is lower than I would like for a medium-sized company at 8.2%. A good margin of safety (MOS) might be the additional convincing I need to buy this stock.

To evaluate MOS, I compare my inputs with Member Sentiment (MS). Out of 71 studies over the past 90 days (my own and one other with invalid Low Stock Price Forecast excluded), projected sales, projected EPS, Forecast High P/E, and Forecast Low P/E average 8.3%, 9.4%, 23.4, and 15, respectively. I’m slightly lower on all inputs. Value Line projects an average annual P/E of 20, which is slightly higher than MS (19.2) and higher than mine (18). All this amounts to the presence of at least some MOS in this study.

MS Low Stock Price Forecast is $61.07. While 12% lower than mine, my Forecast Low P/E is lower. The stock was ~17% lower six weeks ago and 59 of the MS studies were done in those first seven weeks, which might help explain this finding.

Despite the MOS, I am going to wait for slightly lower prices in hopes of seeing a better PAR.

APD Stock Study (2-18-23)

I recently did a stock study on Air Products and Chemicals Inc. (APD) with a closing price of $281.49.

M* writes:

     > Since its founding in 1940, Air Products has become one of the
     > leading industrial gas suppliers globally, with operations in
     > 50 countries and 19,000 employees. The company is the largest
     > supplier of hydrogen and helium in the world. It has a unique
     > portfolio serving customers in a number of industries, including
     > chemicals, energy, healthcare, metals, and electronics.

This large-sized company has grown sales and earnings at annualized rates of 0.8% and 8.9% over the last 10 years, respectively. Sales had a long period of flat time (from ’14-’21) while EPS was only down in ’14 and ’17-’18. Over the last 10 years, PTPM trended higher from 13.3% to 21.7% with a last-5-year average of 24.3%. This leads peer and industry averages. ROE was 15.3% in ’13 and has averaged 15.4% over the last five years. This is about even with the industry while slightly lagging peer averages.

Debt-to-Capital has come down from 47.1% in ’13 to 38.8% in ’22 with a last-5-year average of 33.3%. This is lower than peer and industry averages. As of the most recent quarter, Interest Coverage is 21 and Quick Ratio 1.68. Value Line gives APD an A++ for financial strength and M* rates its capital allocation as Exemplary.

I assume long-term annualized sales growth of 6% based on the following:

• CNN Business projects 4.7% YOY and 5% per year for ’23 and ’22-’24, respectively (based on 23 analysts).
• YF projects YOY 4.2% and 6.1% for ’23 and ’24, respectively (19 analysts).
• Zacks projects YOY 3.4% and 6.9% for ’23 and ’24, respectively (6).
• Value Line projects 8.3% from ’22-’26.
• CFRA projects 5.1% YOY and 10.2% per year for ’23 and ’22-’24.
• M* gives a 2-year annualized ACE of 6%.

I assume long-term annualized EPS growth of 8% based on the following:

• CNN Business projects 9% YOY and 9.6% per year for ’23 and ’22-’24, respectively (based on 23 analysts), along with a 5-year annualized rate of 10.2%.
• MarketWatch projects 10.4% and 10.9% per year for ’22-’24 and ’22-’25, respectively (28 analysts).
• Nasdaq.com projects 8.7% YOY and 9.6% per year for ’24 and ’23-’25, respectively (8, 8, and 5 analysts for ’23, ’24, and ’25).
• Seeking Alpha projects 4-year annualized growth of 10.9%.
• YF projects YOY 8.7% and 10.2% for ’23 and ’24, respectively (21), along with 5-year annualized growth of 8.8%.
• Zacks projects YOY 9.4% and 8.7% for ’23 and ’24, respectively (8), along with 5-year annualized growth of 11.7%.
• Value Line projects annualized growth of 11.6% from ’22-’26.
• CFRA projects 10.5% YOY and 12% per year for ’23 and ’22-’24, respectively, and 12% per year from ’21-’24.
• M* estimates long-term growth of 14.5%.

I am forecasting below all six long-term estimates (mean 11.3%).

My Forecast High P/E is 22. High P/E has trended up from 22.4 (’13) to 31.4 (’22) with a last-5-year average of 31.9. I’m projecting just below the entire range.

My Forecast Low P/E is 20. Low P/E has trended up from 15 (’13) to 21.5 (’22) with a last-5-year average of 21.9. I’d like to use 18, but the market has been very bullish recently.

My Low Stock Price Forecast is the default value of $202.60. This is 28% below the previous closing price and 6.3% below the ’21-’22 low of $216.20. I think this is reasonable despite being more aggressive with my Forecast Low P/E.

Over the last 10 years, Payout Ratio has ranged from 48.8% (’16) to 71.9% (’17) with a last-5-year average of 62%. I am estimating low at 48%.

These inputs land APD in the HOLD zone with an U/D ratio of 1.0. The Total Annualized Return is 7.5%.

PAR (using forecast average, not high, P/E) is 5.9%: less than I seek for a large company. Like many other stocks, this is a tough time to buy with shares up ~23% in the last four months.

To assess margin of safety (MOS), I compare my inputs with those of Member Sentiment (MS). Out of 116 studies over the past 90 days (my own excluded), projected sales growth, EPS growth, Forecast High P/E, Forecast Low P/E, and Payout Ratio average 7.3%, 10.6%, 28.4, 21.3, and 66.4%, respectively. I am lower on all inputs. Value Line projects an average annual P/E of 23.5: lower than MS (24.9) and higher than mine (21). MS Low Stock Price Forecast is almost identical to mine at $202.4. All this is indicative of a healthy MOS for the study.

I would feel comfortable buying APD under $241/share.

LULU Stock Study (1-25-23)

I recently did a stock study on Lululemon Athletica Inc. (LULU) with a closing price of $311.21.

M* writes:

     > Lululemon Athletica Inc. designs, distributes, and markets
     > athletic apparel, footwear, and accessories for women, men,
     > and girls. Lululemon offers pants, shorts, tops, and jackets
     > for both leisure and athletic activities such as yoga and
     > running. The company also sells fitness accessories, such
     > as bags, yoga mats, and equipment.

This medium-sized company has grown sales and EPS at rates of 17.3% and 16.9% per year since 2012. Lines are mostly up (EPS dipped in ’14, ’17, and ’20), straight, and parallel. PTPM over the last 10 years has fallen from 27.8% in ’12 to 21.3% in ’21 with a last-5-year average of 20.3%. This beats peer (stated as BOOT, BURL, and VSCO) and industry averages.

ROE over the last 10 years has ranged from 16.8% (’17) to 39% (’19) with a 5-year average of 30.6%: slightly better than industry averages and solidly better than peer averages. Debt-to-Capital was zero through 2018. The 5-year average is now 15.1%—much lower than peer and industry averages—while the company maintains zero long-term debt

I assume long-term annualized sales growth of 15% based on the following:

• CNN Business projects 27% YOY and 28% per year for ’23 and ’22-’24, respectively (based on 28 analysts).
• YF projects YOY 28.3% and 13.7% for ’23 and ’24, respectively (29 analysts).
• Zacks projects YOY 28.3% and 13.2% for ’23 and ’24, respectively (13).
• Value Line projects 15.7% growth per year from ’21-’26.
• CFRA projects 29.5% YOY and 20.6% per year for ’23 and ’22-’24, respectively.
• M* gives a 2-year ACE of 18.6%

I assume long-term annualized EPS growth of 15% based on the following:

• CNN Business reports ACE of 27.3% YOY and 20.7% per year for ’23 and ’22-’24, respectively (based on 28 analysts).
• MarketWatch projects annualized ACE of 21.5% and 20.3% from ’22-’24 and ’22-’25, respectively (33 analysts).
• Nasdaq.com projects annualized growth of 16.4% and 13.6% for ’23-’25 and ’23-’26, respectively (15, 11, and 2 analysts for ’23, ’25, and ’26).
• YF projects YOY 27.3% and 15% for ’23 and ’24, respectively, and 21.9% per year for the next five years (29).
• Zacks projects YOY 27.2% and 14.4% for ’23 and ’24, respectively, and 20% per year for the next five years (13).
• Value Line projects annualized growth of 18.2% from ’21-’26.
• CFRA projects 28.4% YOY and 21.5% for ’23 and ’22-’24, respectively, with 3-year annualized EPS growth of 28%.
• M* gives a long-term ACE of 20.2% per year.

My Forecast High P/E is 34. High P/E has ranged from 37 (’15 and ’16) to 88.9 (upside outlier in ’20) over the last 10 years. The last 5-year average excluding ’20 is 50.9 and trending higher.

Forecast Low P/E is 24. Low P/E has ranged from 20.7 (’18) to 36 (’21) over the last 10 years. The last-5-year average is 27.8.

My Low Stock Price Forecast is $218.40. This is sticking with default and 30% below the previous closing price.

All this results in an U/D ratio of 3.1, which makes LULU a Buy. Total Annualized Return is 14.5%.

While 14.5% is a solid total return, I believe PAR (based on Forecast Average, not High, P/E) to be more realistic. I think PAR of 10.9% is acceptable for a medium-sized company especially if it has a decent chance of beating my estimates.

Despite originally using an 18% growth projection as a number on lower end of analyst long-term forecasts (including all the long-term EPS forecasts), I discounted to 15% for the final study. This provides some margin of safety (MOS).

As a more comprehensive MOS check, I looked at Member Sentiment (MS) averages of 189 studies over the past 90 days. Projected sales, projected EPS, Forecast High P/E, and Forecast Low P/E average 16.3%, 16%, 41.8, and 26.6, respectively. I’m lower on all inputs—especially with regard to the P/E range. MS average P/E is 34.7 compared to my 29 (and Value Line’s 32). If I exclude stock studies with projected low price of $50 or lower, which I consider unreasonable, then MS projects a low price of $218.94, which is roughly equal to mine.

I feel confident buying LULU up to $319/share.

CPRT Stock Study (1-24-23)

I recently did a stock study on Copart, Inc. (CPRT) with a closing price of $64.86.

CFRA writes:

     > Founded in 1982 and headquartered in Dallas, CPRT is a global
     > global leader in online vehicle auctions. Copart’s online
     > auction platform links sellers to more than 750,000 members
     > in over 170 countries. The company offers services to process
     > and sell salvage and clean title vehicles to dealers,
     > dismantlers, rebuilders, exporters, and in some cases,
     > individuals. Copart sells vehicles on behalf of insurance
     > companies, banks, finance companies, charities, fleet operators
     > and dealers, and individual owners.

This medium-sized company has grown sales and earnings at annualized rates of 14% and 25.7%, respectively, over the last 10 years. Lines are mostly up, straight, and parallel. Over the last 10 years, PTPM has trended higher from 26.5% to 38.3% with a 5-year average of 36.4%. This far outpaces peer (stated as CRMT, ABG, and LAZY) and industry averages.

ROE has been up and down over the last 10 years with a 5-year average of 29.2%—slightly higher than peer and industry averages. Debt-to-Capital has decreased from 33.8% to 2.5% over the last 10 years with a last-5-year average of 14.2%. This is much lower than peer and industry averages. Current and Quick Ratios are over 4 while Interest Coverage over the last five years is an impressive 48.

I assume long-term annualized sales growth of 4% based on the following:

• CNN Business (FactSet) projects 8.6% YOY and 6.9% per year for ’23 and ’22-’24, respectively, based on eight analysts.
• YF projects 7.8% and 7.3% YOY for ’23 and ’24, respectively (eight analysts).
• Zacks projects YOY 7.1% and 7% for ’23 and ’24, respectively (4).
• Value Line projects 6.5% annualized from ’20-’22 through ’25-’27, but only 2.7% annualized from ’22-’26 (base effects; earnings grew about 20% YOY in ’22).
• M* offers a 2-year ACE of 7% per year.
• CFRA projects 7.9% YOY and 7.2% per year for ’23 and ’22-’24, respectively.

I assume long-term annualized EPS growth of 4% based on the following:

• CNN Business (FactSet) reports ACE 3.6% YOY and 6.7% per year for ’23 and ’22-’24, respectively, based on eight analysts.
• MarketWatch (FactSet) projects 6.7% and 13.1% per year from ’22-’24 and ’22-’25, respectively (10 analysts).
• Nasdaq.com (Zacks) projects 7.6% YOY and 6.1% per year for ’24 and ’23-’25, respectively (5, 5, and 2 analysts for ’23, ’24, and ’25).
• YF projects 3.6% and 10.4% YOY for ’23 and ’24, respectively, and 22.3% per year for the next five years (9).
• Zacks projects 0.5% and 7.6% YOY for ’23 and ’24, respectively (5).
• Value Line projects 2.9% per year from ’22-’26.
• CFRA projects 3.1% YOY and 6.9% per year for ’23 and ’22-’24, respectively, along with a 3-year annualized projection of 11%.

I’m using Forecast High P/E of 30. High P/E over the last 10 years has ranged from 19.4 (’17) – 37.9 (’21). The last five years have trended higher with an average of 35.3.

I’m using Forecast Low P/E of 17. Low P/E over the last 10 years has ranged from 14.6 (’16) – 23.9 (’21). The last five years have averaged 20.2.

I’m using a Low Stock Price Forecast of $46.60. The default low price is $37.90, which is 41% below the previous closing price. I selected the 2021 low price, which is about 28% below the previous closing price.

All this results in an U/D ratio of 0.9, which makes CPRT a Hold. Total Annualized Return is 4.7%.

PAR (based on Forecast Average, rather than High P/E) is -0.3%, which echoes Value Line’s statement that “shares… have unappealing long-term appreciation potential, at the current quotation.”

I did not feel particularly conservative with this study, which might mean even -0.3% per year is too optimistic. To better assess this, I look to Member Sentiment. Based on 187 studies in last 90 days, averages for projected sales growth, EPS growth, High P/E, and Low P/E are 8.8%, 10.5%, 31, and 19.2, respectively. I’m actually lower on all inputs. As one additional reference point, Value Line projects an average annual P/E of 27 compared to my 23.5.

My study therefore does appear to be rather conservative. Unfortunately at this time CPRT is far too overpriced to get the sort of annualized return I would hope to realize from a medium-sized company. I will wait to reassess at the upper end of the Buy zone: $55/share.

MMM Stock Study (1-24-23)

I recently did a stock study on 3M Co. (MMM) with a closing price of $122.62.

CFRA writes:

     > 3M Co. is a global manufacturer operating a diversified business.
     > The firm classifies its business into four reportable segments —
     > Safety & Industrial, Transportation & Electronics, Health Care,
     > and Consumer. Most 3M products involve expertise in product
     > development, manufacturing, and marketing, with many of the
     > company’s products involving some form of coating, sealant,
     > adhesive, film or chemical additive that increases the product’s
     > overall functionality and useability for customers.

This large company was recently presented in the Aug 2022 Manifest Investing Round Table. It was also selected (out of four stocks) via audience poll to be the newest monthly addition to the portfolio. MMM is a DJI component.

I hesitate to call this a “high quality growth stock” because the historical growth has been so low. Personally, I would have panned it. I am doing this study for educational purposes to see if I can uncover any unexpected merit.

Over the last 10 years, 3M has grown sales and EPS at annualized rates of 1.3% and 4.4%, respectively. Lines are somewhat up and parallel (I guess?) with some pullbacks. I would not blame anyone for passing on the stock based on visual inspection alone [a la “barbed wire fence”].

Over the last 10 years, PTPM is relatively consistent with a last-5-year average of 20.9%. This is higher than peer (stated as HON and BBU) and industry averages. ROE has been trending higher over the last 10 years with a 5-year average of 43.2%—also higher than peer and industry averages.

Debt-to-Capital has been trending higher over the last 10 years. The last-5-year average is 59.6%. While somewhat uncomfortable, this is generally lower than peer and industry averages. Quick Ratio is a lackluster 0.87. Interest Coverage is better at 16.

I assume long-term annualized sales growth of 1% based on the following:

• CNN Business projects 3.4% YOY contraction and 3% contraction per year for ’22 and ’21-’23, respectively (based on 17 analysts).
• YF projects YOY contraction of 3.3% and 2.4% for ’22 and ’23, respectively (20 analysts).
• Zacks projects YOY contraction of 3.4% and 3.1% for ’22 and ’23, respectively (5).
• Value Line projects 3.5% growth per year from ’21-’26.
• Morningstar offers a 2-year ACE of 2.1% contraction per year.
• CFRA projects 1% per year contraction and 3% per year growth for ’21-’23 and ’21-’24, respectively.

I almost feel 1% is generous based on these estimates.

I assume long-term annualized EPS growth of 1% based on the following:

• CNN Business projects growth of 1.5% YOY and 0.5% per year for ’22 and ’21-’23, respectively, based on 17 analysts.
• MarketWatch projects annualized growth of 2% and 3.2% from ’21-’23 and ’21-’24, respectively (22 analysts).
• Nasdaq.com projects annualized contraction of 0.2% and 1.4% for ’22-’24 and ’24-’25, respectively [7, 4, and 1 analyst(s) for ’22, ’24, and ’25].
• YF projects YOY growth of 0.6% and 0.4% for ’22 and ’23, respectively, and 0.7% per year contraction for the next five years (20).
• Zacks projects YOY growth of 0.5% and 0.2% for ’22 and ’23, respectively, and 9.5% growth per year for the next five years (7).
• Value Line projects 7.1% growth per year from ’21-’26.
• M* has long-term ACE at 3.2% growth per year.
• CFRA projects 4.7% per year contraction and 0.2% per year growth for ’21-’23 and ’21-’24, respectively, along with 3-year annualized growth of 4%.

Because Q3 shows an [anomalous?] earnings spike to $11.48/share, I am projecting from the last annual data point [$10.12].

I’m using a forecast High P/E of 19. High P/E over the last 10 years has ranged from 15.1 (’12) – 30.8 (’17) with a last-5-year average of 25.7.

I’m using a forecast Low P/E of 12. Low P/E over the last 10 years has ranged from 12.3 (’20) – 21.9 (’17) with a last-5-year average of 17.9.

I’m using a Low Stock Price Forecast of $96. This is roughly 20% below the previous closing price and at least 11% below the default low price, 2020 low stock price, and 2021 low stock price.

All this results in an U/D ratio of 3.3, which makes MMM a Buy. Total Annualized Return is 13%.

Payout Ratio has trended higher over the last 10 years from 37.3% to 58.5% with a 5-year average of 60.6% (excluding 73.8% in 2019, which seems to be an upside outlier). I am estimating conservatively at 40%. This results in a PAR (using forecast average P/E rather than forecast High P/E) of 9%, which is pretty good for a large-size company.

I’m admittedly surprised to see a Buy here because I cut the estimates to minimal values while still maintaining some growth.

Furthermore, MMM is a Buy even with a margin of safety built into this study. Based on 186 Member Sentiment studies in last 90 days, averages for projected sales growth, projected EPS growth, forecast High P/E, and forecast Low P/E are 2.7%, 4.8%, 21.8, and 16.5, respectively. I’m lower on all inputs. As one additional reference point, Value Line projects an average annual P/E of 17 compared to my 15.5.

CBRE Stock Study (1-21-23)

I recently did a stock study on CBRE Group, Inc. (CBRE) with a closing price of $84.29.

Value Line writes:

     > CBRE Group, Inc. is a worldwide commercial real estate firm, offering
     > services to occupiers, owners, lenders, and investors in the office,
     > retail, industrial, and multi-family segments of the market. Provides
     > facilities management, leasing, property sales, mortgage origination,
     > investment management, and valuation services.

This large-sized company has grown both sales and revenue at an annualized rate of 18.8% for the last 10 years. Lines are mostly up, straight, and parallel except a temporary drop in ’20 EPS before rebounding to the trendline in ’21. PTPM has trended flat over the last 10 years with a 5-year average of 6.6%; this is on par with both peer (stated as JLL and BEKE) and industry averages.

ROE has been consistent over the last 10 years and ahead of peer and industry averages. The 5-year average is 19.4% (21.5% without 2020 downside outlier). Debt-to-Capital has fallen over the last 10 years from 71% to 33% and is slightly higher than peer and industry averages. The last-5-year average is 37.8%. Interest Coverage is a formidable 25.

I assume long-term annualized sales growth of 5% based on the following:

• CNN Business projects 10.5% YOY and 6.6% per year for ’22 and ’21-’23, respectively (based on 10 analysts).
• YF projects YOY 10.7% and 3.5% for ’22 and ’23, respectively (8 analysts).
• Zacks projects YOY growth of 10.9% and 4.6% for ’22 and ’23, respectively (3).
• Value Line projects 4.8% annualized growth from ’21-’26.
• Morningstar offers a 2-year ACE of 7% per year.

I assume long-term annualized EPS growth of 5% based on the following:

• CNN Business projects 4.5% YOY growth and 0.8% per year contraction for ’22 and ’21-’23, respectively (based on 10 analysts).
• MarketWatch projects contraction of 1.6% per year and growth of 4.5% per year for ’21-’23 and ’21-’24, respectively (10 analysts).
• Nasdaq.com projects 6% and 10.7% growth per year for ’22-’24 and ’22-’25, respectively [4, 4, and 1 analyst(s) for ’22, ’24, and ’25].
• YF projects 5.1% growth for ’22, 6.1% contraction for ’23, and 11% annualized growth for the next five years (8).
• Zacks projects YOY contraction of 4.1% and 2.9% for ’22 and ’23, respectively (4).
• Value Line projects 2.8% growth per year from ’21-’26 (statistical array) while also projecting 8.5% growth per year from ’19-’21 through ’25-’27 (left margin).
• Morningstar offers a long-term growth estimate of 6.1% per year.

I’m using a forecast High P/E of 16. High P/E has ranged from 16.3 (’18) to 30.5 (’20) over the last 10 years. Excluding the latter as an upside outlier, the last four years have averaged 18.7 and the trend has been down.

I’m using a forecast Low P/E of 10. Low P/E has ranged from 10 (’19) to 21 (’13) over the last 10 years. The trend has been down with a last-5-year average of 12.1.

I’m sticking with default and using a Low Stock Price Forecast of $60. This is ~29% below the previous closing price and near the ’21 low.

All this results in an U/D ratio of 1.7, which makes CBRE a Hold. Total Annualized Return (TAR) is 7%. PAR (using projected average P/E rather than High P/E) is 2.6%, which is lower than I seek in a long-term stock investment.

To add more context behind this study, I look at Member Sentiment (MS). Based on 97 studies over the past 90 days, averages for projected sales growth, projected EPS growth, High P/E, and Low P/E are 7.9%, 8.5%, 20.2, and 12.8, respectively. I’m lower on all inputs. This represents a margin of safety that increases the probability TAR may be achieved.

I still want TAR to be higher, though. I am looking for $76/share (10% discount to today’s price) as an entry point for this stock.

BLDR Stock Study (1-19-23)

I recently did a stock study on Builders FirstSource (BLDR) with a closing price of $71.69.

Value Line writes:

     > Builders FirstSource, Inc. manufactures and sells a wide variety of
     > building materials, including lumber, floor & roofing products, windows
     > & doors, insulation, siding, and cement. Its customers are
     > homebuilders, remodelers, and commercial contractors.

This large-sized company has grown sales at 34.2% per year for the last 10 years. EPS has grown 56.8% per year since 2016 [excluding 2012-2015, which ranged from -$0.44/share to +$0.57/share]. Lines are mostly up and parallel except for ’17 EPS, which dipped to $0.34/share. PTPM has trended gradually higher with a 5-year average of 4.9%, which trails peer (stated as JCI, TT, and CARR) and industry averages.

ROE has averaged 26.8% over the last five years, which is similar to peer and industry averages. Debt-to-Capital averages a higher-than-desired 64.9% over the last five years. This is falling, though, and recently (’21) crossed below peer and industry averages. Interest Coverage is a comfortable 19.

I assume long-term annualized sales growth of 4% based on the following:

• CNN Business projects 13.6% YOY growth and a 14.2% per year contraction for ’22 and ’21-’23, respectively (based on 14 analysts).
• YF projects 13.6% YOY growth and 41.2% YOY contraction for ’22 and ’23, respectively (13 analysts).
• Zacks projects 13.3% YOY growth and 28.7% YOY contraction for ’22 and ’23, respectively (7).
• Value Line projects 6.9% annualized growth from ’21-’26.
• Morningstar offers a 2-year ACE of 14.3% annualized contraction.

I assume long-term annualized EPS growth of 3% based on the following:

• CNN Business reports ACE of 69.5% YOY growth and a 24.7% per year contraction for ’22 and ’21-’23, respectively (based on 14 analysts).
• MarketWatch projects annualized contraction of 18.8% and 7.1% for ’21-’23 and ’21-’24, respectively (14 analysts).
• Nasdaq.com projects 62.4% YOY contraction and 32.8% per year contraction for ’23 and ’22-’24, respectively (7, 8, and 5 analysts for ’22, ’23 and ’24).
• YF projects 72.7% growth for ’22, 67% contraction for ’23, and 18.8% annualized growth for the next five years (13).
• Zacks projects 72.9% YOY growth for ’22 and 62.4% YOY contraction for ’23 (7).
• Value Line projects 7.8% annualized growth from ’21-’26 while also projecting 17.5% annualized growth from ’20-’26.*

Across the homebuilding and building materials industries, everyone seems to expect a slowdown for ’23. BLDR earnings aren’t expected to come anywhere close to recovering through ’24. Anything can happen, but after a soft ’23 and ’24, for the 5-year growth rate to be 7.8% or in the high teens (per the two LT estimates available) would require ’25 and ’26 to be explosive. I can’t just assume that being 3-4 years into the future.

I’m using a forecast High P/E of 8. High P/E has ranged from NMF to 64.9 (’17) over the last 10 years. Excluding the latter as an upside outlier, the last four years have averaged 13.3—the lowest of which was 10.2 in ’21.

I’m using a forecast Low P/E of 3. Low P/E has ranged from NMF to 31.1 (’17) over the last 10 years. The last four years have averaged 4.8 with a low of 3.4 in ’20. The current P/E is 4.4.

I’m sticking with default and using a Low Stock Price Forecast of $49. This is near the 52-week low price and 31.6% below the previous close.

All this results in an U/D ratio of 3.5, which makes BLDR a Buy. Total Annualized Return (TAR) is 16.1%.

PAR, which uses projected average (rather than high) P/E, is 7.8%. This is not bad for a large company, but I would like to see better unless I can feel confident in the company’s chances to exceed projected growth rates.

To assess that, I check for a margin of safety (MOS) by comparing with Member Sentiment (MS). Based on 73 studies over the past 90 days, MS indicates averages for projected sales growth, projected EPS growth, High P/E, and Low P/E are 10.6%, 8.4%, 12.6, and 8, respectively. I’m more than 50% lower on three inputs and about 33% lower on High P/E.

In addition to using conservative inputs given scant long-term analyst estimates and current uncertainty, MS implies a healthy MOS in this study. That increases likelihood of realizing TAR.

MS has a lower Low Stock Price Forecast at $44.26, but it’s hard to draw any direct conclusions from this. $44.26 would lower the upper Buy threshold in my study to $71 and make the stock a Hold. This also effectively lowers forecast Low P/E on which I’m already quite low (3) along with my entire forecast P/E range.

Taking everything into consideration, I feel comfortable with a Buy up to $74/share.

* — In and of itself, this demands a wholly separate discussion.

CTSH Stock Study (1-19-23)

I recently did a stock study on Cognizant Technology Solutions (CTSH) with a closing price of $60.99.

Since 2012, this large-sized company has grown sales and EPS at annualized rates of 10.2% and 7.5%, respectively. Lines are mostly up, straight, and parallel with some rockiness in EPS (down in ’16, ’17, ’19, and ’20). PTPM has trended lower over that timeframe with a 5-year average of 15.7%. This leads peer (stated as LDOS and CDW) and industry averages.

ROE has also trended lower with a last-5-year average of 16%. This trails peer and industry averages. Debt-to-capital averages 10.6% over the last five years, which is far below peer and industry averages. Interest Coverage is a whopping 234.

M* writes:

     > Cognizant is a global IT services provider, offering consulting and
     > outsourcing services to some of the world’s largest enterprises spanning
     > the financial services, media and communications, healthcare, natural
     > resources, and consumer products industries.

I assume long-term annualized sales growth of 4% based on the following:

• CNN Business projects growth of 4.9% YOY and 4.2% per year for ’22 and ’21-’23, respectively (based on 23 analysts).
• YF projects 4.6% and 3.9% YOY growth for ’22 and ’23, respectively (26).
• Zacks projects 4.5% and 3.3% YOY growth for ’22 and ’23, respectively (7).
• CFRA projects growth of 4.5% YOY and 4.8% per year for ’22 and ’21-’23, respectively.
• Value Line projects 5.8% annualized growth from ’21-’26.
• M* offers a 2-year ACE of 4.7% per year.

I assume long-term annualized EPS growth of 6% based on the following:

• CNN Business reports ACE of 7.5% YOY and 6.6% per year growth for ’22 and ’21-’23, respectively (based on 23 analysts).
• MarketWatch projects growth of 7.5% and 7.7% per year for ’21-’23 and ’21-’24, respectively (28).
• Nasdaq.com projects 6.1% YOY growth and 7.3% growth per year for ’23 and ’22-’24, respectively (3, 10, and 6 analysts for ’22, ’23, and ’24).
• YF projects 7.6% growth for ’22, 6.6% growth for ’23, and 5.4% annualized growth for the next five years (25).
• Zacks projects 7.8% growth for ’22, 5.6% growth for ’23, and 11% annualized growth for the next five years (7).
• Value Line projects 7.4% growth per year from ’21-’26.
• CFRA projects 7.5% YOY growth for ’22, 8.6% growth per year for ’21-’23, and 3-year EPS annualized growth of 7%.

I project a future High P/E of 20. High P/E has ranged from 22.2 (’21) to 32.2 (’20) over the last 10 years with a 5-year average of 26.2.

I project a future Low P/E of 12. Low P/E has ranged from 15.1 (’13) to 20.4 (’17) with a 5-year average of 17.2.

I project a future low price of $45. The default price of $54 is only 11% below the previous closing price; the rule of thumb is to go at least 20% below. The 52-week low ($51) is 16% less and the 2020 low ($40) is 34% less. I am choosing a number in the middle of these two (26.2% less).

All this results in an U/D ratio of 3.2, which puts CTSH in the Buy zone. CAR (using forecast High P/E) is 15.1%.

Payout Ratio has a last-5-year average of 24.5% (range 17.8% to 34.2%). I’m using 17% to be conservative.

PAR, which uses projected average P/E, is 10.4%: not terrible for a large company.

Let’s look at Member Sentiment (MS) to assess margin of safety (MOS). Based on 428 studies over the past 90 days, averages for projected sales growth, projected EPS growth, High P/E, and Low P/E are 7.4%, 9.2%, 22.7, and 16, respectively. I’m lower on all inputs. I also further lowered projected Low Price, which in effect is lowering my forecast Low P/E. I’m lower than MS average low price of $50.79. As a final check, Value Line projects an average annual P/E of 17. I’m lower at 16.

As my study appears to have a healthy MOS, I feel comfortable with a Buy up to $63/share.